Insights & news

Outgoing U.S. Administration Adopts Most Favoured Nation Payment Model for Medicines

  • 23/11/2020
  • News

On 20 November 2020, U.S. Department of Health and Human Services Secretary Alex Azar announced the creation of a medicine payment model that would reduce the price of specific medicines in the United States to the level of the lowest price for similar medicines in comparison countries (see, attached press release). The model, now dubbed Most Favoured Nation (MFN) Model, follows a plan (see, Van Bael & Bellis Life Sciences News Alert of 14 May 2018) and a series of Executive Orders of the U.S. President to bring medicine prices down for U.S. patients while terminating what the President has repeatedly referred to as “foreign freeriding” (see, Van Bael & Bellis Life Sciences News Alert of 15 September 2020 for a discussion of the most recent Executive Order on the subject). 
The MFN Model will operate for seven years and will apply to 50 medicines, including biological products, with the highest what is known as “Medicare Part B spending”. This refers, broadly, to medicines provided in physicians’ offices and hospital outpatient departments. Participating entities will receive the model payment for these 50 medicines rather than their current average sales price plus a 6 percent add-on. The model payment will encompass two parts: (i) an amount based on the lowest price in comparison countries blended with the average sales price; and (ii) a flat add-on. The formula for blending in the foreign price in part (i) will evolve as a function of the development of U.S. prices. The model also includes protections for beneficiaries (such as a continued choice of providers and treatments) and a financial hardship type of protection for specific MFN participants. Details of the MFN Model can be found in the attached fact sheet.
The MFN Model will form the subject of a 60-day public consultation. It comes at a peculiar time given the impending change of administration. Still, it is a reminder of the reality that U.S. medicine prices are the highest in the world and that some form of international reference pricing may end up being employed in the U.S. as well. 


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 18/01/2021
    • Articles

    Belgium – Publication of Law on Medical Devices

    The Belgian Official Journal publishes today (i.e., 18 January 2021) the Law of 22 December 2020 on medical devices (Wet van 22 december 2020 betreffende medische hulpmiddelen / Loi du 22 décembre 2020 relative aux dispositifs médicaux – the Law). The Law implements in Belgium (i) Regulation (EU) 2017/745 of 5 April 2017 on medical devices (the MDR); and (ii) chapter IV of Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices, i.e., the chapter on notified bodies. Following its adoption by the federal Chamber of Representatives’ Committee for Public Health and Equal Opportunities on 8 December 2020, the Law was adopted in plenary session on 17 December 2020. The adopted text is identical to that of the Bill which the federal Government submitted to the Chamber of Representatives on 29 September 2020. For a discussion of the Law, we refer to our news alert of 3 December 2020 (see, Van Bael & Bellis Life Sciences News Alert of 3 December 2020). Subject to exceptions, the Law will enter into force on 26 May 2021, i.e., on the currently scheduled date of entry into force of the MDR.

    Read more
    • 06/01/2021
    • Articles

    Covid-19 Vaccine Moderna® Is Second Covid-19 Vaccine Recommended by European Medicines Agency for Use in European Union

    The European Medicines Agency (EMA) issued today its recommendation that the European Commission (the Commission) should grant a conditional marketing authorisation for the vaccine Covid-19 Vaccine Moderna®, a medicine developed by Moderna which will be indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older (see, attached press release). The Commission is expected to give its approval shortly, possibly still today, paving the way for an expansion of existing vaccination programmes in the European Union. The recommendation follows a similar recommendation given on 21 December 2020 for Comirnaty®, a vaccine developed by BioNTech and Pfizer (see, Van Bael & Bellis Life Sciences News Alert of 21 December 2020). As is the case for Comirnaty®, Covid-19 Vaccine Moderna® contains a molecule called messenger ribonucleic acid (mRNA) which harbours instructions for making the spike protein which is characteristic of the SARS-CoV-2 virus and allows the virus to enter the human body’s cells. The vaccine thus causes the recipient’s body to recognise and produce the spike protein temporarily which, in turn, will activate the person’s immune system and cause it to produce antibodies and activate white blood cells to attack it. The person’s immune system is thus readied for an attack with the genuine SARS-CoV-2 virus and defend the body against it. The EMA made its recommendation on the basis of placebo-controlled clinical trial data involving 30,000 people. Efficacy was calculated in around 28,000 persons and showed a significant 94.1% reduction in the number of symptomatic Covid-19 cases in persons who were given the vaccine compared with persons from the control group who received a dummy injection. These strong results applied irrespective of pre-existing risk-enhancing conditions such as chronic lung disease, heart disease or diabetes and regardless of age (18 and up), gender, race or ethnicity. The marketing authorisation awarded to Covid-19 Vaccine Moderna® will be conditional in that the marketing authorisation holder will be required to continue providing results from the ongoing main trial which is scheduled to last two years. Additional trials will seek to gain fresh information regarding the length of protection afforded, the level of protection created against severe Covid-19 infections and the degree of protection established for the benefit of specific groups, including immunocompromised patients, children, and pregnant women. Further research will also focus on the vaccine’s ability to prevent asymptomatic cases. Other checks will result from the application of the EU’s safety monitoring plan for Covid-19 vaccines and from the risk management plan for Covid-19 Vaccine Moderna®.

    Read more
    • 04/01/2021
    • News

    Medicinal Products under the EU-UK Trade and Cooperation Agreement

    The attached note discusses the status of medicinal products under the recent EU-UK Trade and Cooperation Agreement

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *